DK1140168T3 - Anvendelse af antistoffer til vaccination mod cancer - Google Patents

Anvendelse af antistoffer til vaccination mod cancer

Info

Publication number
DK1140168T3
DK1140168T3 DK00906191T DK00906191T DK1140168T3 DK 1140168 T3 DK1140168 T3 DK 1140168T3 DK 00906191 T DK00906191 T DK 00906191T DK 00906191 T DK00906191 T DK 00906191T DK 1140168 T3 DK1140168 T3 DK 1140168T3
Authority
DK
Denmark
Prior art keywords
against cancer
antibodies
vaccination against
prophylactically
medicament
Prior art date
Application number
DK00906191T
Other languages
Danish (da)
English (en)
Inventor
Helmut Eckert
Hans Loibner
Original Assignee
Igeneon Krebs Immuntherapie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igeneon Krebs Immuntherapie filed Critical Igeneon Krebs Immuntherapie
Application granted granted Critical
Publication of DK1140168T3 publication Critical patent/DK1140168T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK00906191T 1999-01-13 2000-01-12 Anvendelse af antistoffer til vaccination mod cancer DK1140168T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH5199 1999-01-13
PCT/EP2000/000174 WO2000041722A1 (de) 1999-01-13 2000-01-12 Verwendung von antikörpern zur vakzinierung gegen krebs

Publications (1)

Publication Number Publication Date
DK1140168T3 true DK1140168T3 (da) 2002-09-30

Family

ID=4178206

Family Applications (2)

Application Number Title Priority Date Filing Date
DK00906191T DK1140168T3 (da) 1999-01-13 2000-01-12 Anvendelse af antistoffer til vaccination mod cancer
DK02005394T DK1230932T3 (da) 1999-01-13 2000-01-12 Anvendelse af antistoffer til vaccinering mod cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK02005394T DK1230932T3 (da) 1999-01-13 2000-01-12 Anvendelse af antistoffer til vaccinering mod cancer

Country Status (28)

Country Link
US (3) US7691372B2 (cs)
EP (2) EP1140168B1 (cs)
JP (1) JP4774551B2 (cs)
KR (1) KR100771752B1 (cs)
CN (1) CN1188169C (cs)
AT (2) ATE286745T1 (cs)
AU (1) AU768515B2 (cs)
CA (1) CA2360382C (cs)
CZ (1) CZ302801B6 (cs)
DE (2) DE50000243D1 (cs)
DK (2) DK1140168T3 (cs)
EE (1) EE05474B1 (cs)
ES (2) ES2236375T3 (cs)
HK (1) HK1044487B (cs)
HR (1) HRP20010526A2 (cs)
HU (1) HU226150B1 (cs)
ID (1) ID30223A (cs)
IL (2) IL144265A0 (cs)
IS (1) IS5998A (cs)
MX (1) MXPA01007148A (cs)
NO (1) NO329917B1 (cs)
NZ (1) NZ512722A (cs)
PL (1) PL201533B1 (cs)
PT (2) PT1230932E (cs)
SI (2) SI1230932T1 (cs)
SK (1) SK286627B6 (cs)
TR (1) TR200102034T2 (cs)
WO (1) WO2000041722A1 (cs)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ302801B6 (cs) * 1999-01-13 2011-11-16 Igeneon Krebs-Immuntherapie Forschungs Und Entwicklungs-Ag Použití protilátky namírené proti antigenu bunecné membrány Ep-CAM pro výrobu farmaceutického prostredku
AT410172B (de) * 2000-03-21 2003-02-25 Igeneon Gmbh Verfahren zur herstellung einer vakzineformulierung
AT502293B1 (de) * 2002-05-15 2008-03-15 Igeneon Krebs Immuntherapie Immunogener, monoklonaler antikörper
AT500647A1 (de) * 2002-05-21 2006-02-15 Igeneon Krebs Immuntherapie Verwendung eines impfstoffes
AT500650B1 (de) * 2003-04-17 2009-11-15 Altropus Gmbh Immunogener rekombinanter antikörper
AT500651B9 (de) * 2003-05-27 2010-04-15 Altropus Gmbh Aktiv immunisierender antikörper
JP2008505943A (ja) 2004-07-14 2008-02-28 イゲネーオン・クレープス−イムンテラピー・フォルシュングス−ウント・エントヴィックルングス−アクチェンゲゼルシャフト グリコシル化抗体
ATE483473T1 (de) * 2004-07-20 2010-10-15 Altropus Gmbh Verwendung von antikörpern in einer sehr geringen dosis zur impfung gegen krebs
CA2605749C (en) * 2005-04-26 2015-06-30 Eisai Co., Ltd. Compositions and methods for cancer immunotherapy
EP2004695A2 (en) 2005-07-08 2008-12-24 Xencor, Inc. Optimized anti-ep-cam antibodies
EP1762575A1 (en) * 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
AT504231A1 (de) 2006-10-03 2008-04-15 Hans Dr Loibner Prädiktive parameter
BRPI0821165B8 (pt) 2007-12-07 2021-05-25 Nutricia Nv uso de uma composição
CA2744103C (en) 2009-02-24 2018-01-02 Esbatech, An Alcon Biomedical Research Unit Llc Methods for identifying immunobinders of cell-surface antigens
US8887373B2 (en) 2012-02-24 2014-11-18 Covidien Lp Vessel sealing instrument with reduced thermal spread and method of manufacture therefor
US20140276968A1 (en) * 2013-03-14 2014-09-18 Ethicon, Inc. Applicator systems for surgical fasteners
US10196458B2 (en) * 2013-07-26 2019-02-05 The Regents Of The University Of California Anti-immunoglobulin E antibodies and methods of using thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341281C (en) * 1986-07-09 2001-08-07 Hubert J.P. Schoemaker Immunotherapy of tumor with monoclonal antibody against the 17-1a antigen
US5270202A (en) 1989-11-03 1993-12-14 Syamal Raychaudhuri Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5798100A (en) * 1994-07-06 1998-08-25 Immunomedics, Inc. Multi-stage cascade boosting vaccine
WO1997005597A1 (en) * 1995-07-31 1997-02-13 Litton Systems Canada Limited Flat panel pixel array incorporating photoconductive switches
EP0857176A1 (en) * 1995-10-25 1998-08-12 Centocor B.V. HUMAN EPITHELIAL ANTIGEN Ep-CAM DERIVED PEPTIDES AND THEIR USE
US6235280B1 (en) 1996-04-12 2001-05-22 Malaya Chatterjee Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
IL121041A0 (en) * 1997-06-09 1997-11-20 Yeda Res & Dev Immunogenic compositions for induction of anti-tumor immunity
US6274143B1 (en) * 1997-06-13 2001-08-14 Malaya Chatterjee Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10
IL139700A (en) * 1998-06-15 2005-09-25 Altarex Medical Corp Immunotherapeutic composition for the treatment of prostate cancer
CZ302801B6 (cs) * 1999-01-13 2011-11-16 Igeneon Krebs-Immuntherapie Forschungs Und Entwicklungs-Ag Použití protilátky namírené proti antigenu bunecné membrány Ep-CAM pro výrobu farmaceutického prostredku
WO2001087233A2 (en) 2000-05-16 2001-11-22 New York University Anti-idiotypic antibody against fimh adhesin of uropathogenic type i-fimbriated escherichia coli, compositions and method of use thereof

Also Published As

Publication number Publication date
IL144265A (en) 2006-08-20
EE200100366A (et) 2002-10-15
MXPA01007148A (es) 2002-03-27
HU226150B1 (en) 2008-05-28
IL144265A0 (en) 2002-05-23
AU768515B2 (en) 2003-12-18
PL364747A1 (en) 2004-12-13
EP1230932A2 (de) 2002-08-14
CN1344167A (zh) 2002-04-10
DK1230932T3 (da) 2005-04-25
NZ512722A (en) 2003-07-25
DE50009240D1 (de) 2005-02-17
EP1230932B1 (de) 2005-01-12
EP1140168A1 (de) 2001-10-10
ATE286745T1 (de) 2005-01-15
ES2236375T3 (es) 2005-07-16
NO20013093L (no) 2001-09-10
HK1044487B (zh) 2005-09-16
HRP20010526A2 (en) 2002-08-31
CZ20012581A3 (cs) 2002-01-16
CA2360382C (en) 2011-05-24
HK1044487A1 (en) 2002-10-25
JP4774551B2 (ja) 2011-09-14
SI1140168T1 (en) 2002-10-31
PT1230932E (pt) 2005-04-29
SK9642001A3 (en) 2002-03-05
CN1188169C (zh) 2005-02-09
KR20010101446A (ko) 2001-11-14
TR200102034T2 (tr) 2001-11-21
US20070224202A1 (en) 2007-09-27
EE05474B1 (et) 2011-10-17
SI1230932T1 (en) 2005-06-30
PL201533B1 (pl) 2009-04-30
CA2360382A1 (en) 2000-07-20
US20120003232A1 (en) 2012-01-05
US20100233178A1 (en) 2010-09-16
SK286627B6 (sk) 2009-02-05
HUP0200527A2 (en) 2002-06-29
IS5998A (is) 2001-07-10
NO329917B1 (no) 2011-01-24
WO2000041722A1 (de) 2000-07-20
AU2796400A (en) 2000-08-01
PT1140168E (pt) 2002-11-29
CZ302801B6 (cs) 2011-11-16
JP2002534481A (ja) 2002-10-15
US8444974B2 (en) 2013-05-21
EP1230932A3 (de) 2003-11-26
US7691372B2 (en) 2010-04-06
KR100771752B1 (ko) 2007-10-30
EP1140168B1 (de) 2002-06-26
ATE219687T1 (de) 2002-07-15
ES2177509T3 (es) 2002-12-16
DE50000243D1 (de) 2002-08-01
NO20013093D0 (no) 2001-06-21
ID30223A (id) 2001-11-15

Similar Documents

Publication Publication Date Title
DK1230932T3 (da) Anvendelse af antistoffer til vaccinering mod cancer
DE60202877D1 (de) Gezieltes antikörper-verfahren
TR200001253T2 (tr) Tümöre özel antijenler
CR8698A (es) Anticuerpos monoclonales al factor de crecimiento de hepatocito
ATE542829T1 (de) Impfstoff
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
BRPI0412245A (pt) anticorpos de rg1 e usos destes
IS7133A (is) Afleiða beta-amyloid - T-frumu-mótefnavísisbóluefni
DK1223980T3 (da) Anvendelse af CSF-1-inhibitorer
CY1110322T1 (el) Αναστολεις της her3 δραστικοτητας
DK1151004T3 (da) Fremgangsmåde til fremstilling af IL-1RA, et terapeutisk protein, ud fra legemsvæsker
CY1113243T1 (el) Μεθοδοι θεραπειας με χρηση αντισωματων cτlα-4
AR016821A1 (es) Procedimiento mejorado para la obtencion de precursores de insulina con puentes de cistina correctamente unidos
BRPI0418317A (pt) vacina de aumento de crescimento à base de epitopo de neutralização
BR0114646A (pt) anticorpos anti-lt-beta-r humanizados
DK1167389T3 (da) Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf
DK1343896T3 (da) Lille syreoplöseligt sporeprotein og anvendelser deraf
ATE490271T1 (de) Rezeptor, dessen verwendung sowie mausantikörper
ATE483473T1 (de) Verwendung von antikörpern in einer sehr geringen dosis zur impfung gegen krebs
AR027540A1 (es) Utilizacion de la proteina mic3 de toxoplasma gondii o de uno de sus derivados como agente inmunogeno o como antigeno de vacunacion
BR0007814A (pt) Uso de anticorpos para a vacinação contra câncer
CY1114835T1 (el) Πληρη ανθρωπινα αντισωματα εναντι ανθρωπινου 4-1ββ (cd137)